Incyte vs its peers
The 10 largest Biotechnology companies by market value, prices of Nov 20, 2026
Incyte is the 8th largest of the 10 biggest Biotechnology companies on OQRO by market value, at $23.4B. Its revenue of $5.14B in fiscal 2025 ranks 6th of 10. It keeps 29% of revenue as operating profit, 5th of 9 (median 29%). Revenue grew 21% on the year before, against a median of +8.0%. At 18.2x its latest annual earnings, the market prices it below its peers (median 26.4x).
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmgenAMGN · FY2025 | $236B | $36.8B | +10.0% | +7.6% | 67.2% | 24.7% | 21.0% | 22.0% | 19.8% | 30.6x | 6.4x | 3.4% | +29.6% |
| Gilead SciencesGILD · FY2025 | $206B | $29.4B | +2.4% | +3.6% | 78.8% | 34.0% | 28.9% | 32.1% | 19.7% | 24.3x | 7.0x | 4.6% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- UTHR47%
- EXEL38%
- VRTX35%
- GILD34%
- INCY29%
- REGN25%
- AMGN25%
- NBIX22%
- MRNA−158%
Compare Incyte head to head
Where Incyte’s revenue comes from and where it goes: Incyte revenue breakdown. Twenty years of results: Incyte financial history.
Common questions
Who are Incyte's competitors?
The largest companies in its industry (Biotechnology) by market value: Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Moderna (MRNA), Biogen (BIIB), United Therapeutics (UTHR), Exelixis (EXEL) and Neurocrine Biosciences (NBIX). They share Incyte's industry listing; not every one competes with it on every product.
Is Incyte bigger than Amgen?
No, by market value: Incyte is worth $23.4B and Amgen $236B. By revenue, Incyte brought in $5.14B in fiscal 2025 and Amgen $36.8B in fiscal 2025.
How does Incyte's valuation compare with its peers?
Incyte trades at 4.5x its annual revenue and 18.2x its net income. The median of the other 9 companies is 6.8x revenue and 26.4x earnings. A higher ratio means investors pay more for each dollar the company makes today, usually because they expect it to grow faster.
Where these figures come from
The group is the companies OQRO lists in the same industry as Incyte (Biotechnology), the largest 9 by market value, plus Incyte. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









